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Aims: To evaluate outcomes of diabetic inpatient hypoglycemia among Aboriginal and Torres Strait 
Islander (ATSI) compared with Australian Caucasian patients.
Methods: A retrospective audit of diabetic patients aged > 18 years admitted at a regional hospital 
general ward between April 1, 2015, and March 31, 2016, was analyzed. The database contains clinical 
information at the time of admission and initial discharge and readmission within 4 weeks thereafter.
Results: A total of 1618 (of 6027) patients were admitted with diabetes representing 23.7% of the 
total ward admissions, of which 484 (29.9%) had inpatient hypoglycemia. Of the 91 patients with 
available data analyzed, ATSI origin with inpatient hypoglycemia was associated with longer length 
of stay (LOS) (hazard ratio [HR], 2.1, 95% confidence interval [CI], 1.2-3.5), whereas severe hypogly-
cemia (≤ 2.2 mmol/L) in both ATSI and non-ATSI was significantly associated with longer LOS (HR, 
2.3; 95% CI, 1.2-4.2). No significant differences in LOS were found for gender, age, and Carlson comor-
bidity index (CCI). The adjusted model for likelihood of readmission, gender, indigenous status, and 
CCI were not significant risk factors for readmission to the hospital. Readmitted patients were older 
(50-59 years vs < 50 years, P = 0.001; 60-69 years vs < 50 years, P = 0.032; 70+ years vs < 50 years, 
P = 0.031).
Conclusion: We reported high rate of inpatient hypoglycemia in our study population. Indigenous 
Australian diabetic patients with inpatient hypoglycemia had significantly longer LOS compared 
with non-Indigenous Caucasian counterparts. Further prospective studies on a larger population are 
needed to confirm our findings.
© Endocrine Society 2020.
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In Australia, there were more than 1 million hospitalizations in 2016 resulting from dia-
betes with disproportionately higher rates of hospitalization among Indigenous Australians 
compared with non-Indigenous counterparts [1]. Aboriginal and Torres Strait Islander 
Australians (ATSI) are 8 times more likely to have diabetes [1]. Although optimal glycemic 
control is needed to prevent chronic complications, diabetic patients on treatment are at 
risk of hypoglycemia, defined as a blood glucose level ≤ 3.9 mmol/L (≤70 mg/dL). Both inpa-
tient and outpatient trials have shown that the risk of hypoglycemia limits achievement of 
good blood glucose control [2].
Several studies have shown an association between severe hypoglycemia and all-cause 
mortality [2, 3]. Despite well-studied consequences of low blood glucose levels in critically 
ill admissions [4–7], the effect of hypoglycemia on outcomes in non-Caucasian cohorts in 
general is least studied [8]. Some studies have shown that general ward hypoglycemia 
in hospitalized Caucasian patients with diabetes is associated with increase in length of 
stay (LOS) [9], mortality [2, 3, 9], and costs [10] but extrapolation of these data onto in-
digenous subpopulations might not be realistic. Some of these studies suggest that the 
increased mortality is not associated with the hypoglycemia itself but rather with the 
patients’ comorbidities [2, 3]. Furthermore, despite a high prevalence of diabetes and its 
complications among the Australian Indigenous population, there is no study on effects of 
inpatient hypoglycemia in its diabetic population.
The aim of this study was to evaluate outcomes of inpatient hypoglycemia in diabetic in-
digenous compared to non-Indigenous Australians.
1. Methods
Data from patients with diabetes who were admitted to a 775-bed teaching hospital be-
tween April 1, 2015, and March 31, 2016, were reviewed. The study was based on a retro-
spective audit carried out using the National Health Roundtable (NHR) registry, electronic 
medical record, and laboratory data (Auslab) provided by the hospital’s Medication Safety 
Committee and the study was approved by the regional ethics committee. The NHR da-
tabase contains clinical information complemented by manual extraction of medication 
and laboratory details from the electronic medical record and Auslab, respectively. Adult 
patients aged > 18 years admitted to the hospital’s general wards were included in the study. 
Information extracted includes gender, age, primary and secondary diagnoses according 
to the International Classification of Diseases, Ninth Revision, Clinical Modification code 
showing admission and discharge status, LOS, indigenous status (dichotomized as ATSI 
and non-ATSI). Medications for diabetes (insulin and/or oral hypoglycemic agents) and 
blood glucose (point of care and/or laboratory) levels were also collated and analyzed.
The NHR database also contains a field that identifies readmission within the 30-day pe-
riod after discharge. The readmission variable is a new hospitalization in the month following 
 discharge with the same major diagnostic category as the initial diagnosis. The analysis includes 
patients discharged within the period of the study with a primary or secondary diagnosis of 
diabetes and a secondary diagnosis of hypoglycemia. Analysis also included demographic char-
acteristics and the presence or absence of coexisting conditions, including congestive heart, 
coronary heart disease, hypercholesterolemia, chronic renal failure, exacerbation of chronic 
pulmonary disease, atrial fibrillation, cerebrovascular disease, dementia, gastric hemorrhagic 
bleeding, neoplasm, hypertension, anemia, nursing home residence, peripheral arterial di-
sease, malnutrition, obesity, and cirrhosis. A diagnosis was considered primary if it was the 
reason for admission; all other diagnoses were considered secondary.
Descriptive analyses for demographic and clinical characteristics were presented as 
means and SDs for continuous variables and frequencies and percentages for categorical 
variables. We used the Charlson Comorbidity Index (CCI) [11] to rank patient illness 
severity based on the number and importance of comorbid diseases. The overall comor-
bidity score ranges were calculated showing the cumulative increased likelihood of 1-year 
mortality. CCI contains 19 groups of comorbidities, each weighted 1 to 6 to reflect their 
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potential influence on mortality. Furthermore, patients were classified into groups based 
on their total CCI scores (mild: 1, 2; moderate, 3, 4; severe, ≥5); hypoglycemia was classi-
fied based on lowest blood glucose values and categorized as previously described [12]: mild 
(3.9-3.1 mmol/L; 70.0-55.0 mg/dL), moderate (3.0-2.3 mmol/L; 54.0-40.0 mg/dL), and severe 
(≤ 2.2 mmol\L; ≤ 40.0 mg/dL).
Associations between all explanatory variables and categorical response variables (in-
patient mortality and the likelihood of readmission) were assessed separately using uni-
variate logistic regression as preliminary analysis. Multivariable logistic regression was 
applied to inpatient mortality and readmission separately to investigate their association 
with hypoglycemia while adjusting for age, gender, indigenous status, lowest blood glucose 
level (BGL) during hypoglycemic event and the Charlson index score. Adjusted odds ratios 
and 95% confidence interval (CI) were presented for categorical variables. The survival risk 
(hazard ratio [HR]) was computed with the HR estimated from the Cox regression model. In 
this study, survival refers to patients who survived after being discharged from the hospital.
Because of the small events size and limited data, we used Firth penalized likelihood method 
to fit the logistic models and Cox regression. Inference was based on 5% level of significance 
and all statistical analyses was performed in SAS 9.4 software (SAS Institute Inc., Cary, NC) 
and R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
2. Results
A total of 6027 patients were admitted during the period of the study. We identified 1618 
patients admitted with diabetes, representing 23.7% of the total ward admissions. Of these, 
hypoglycemic events were documented in 484 patients (29.9%). A follow-up retrospective 
study of a cohort of 91 patients whose data were available for review and fulfilled inclu-
sion criteria were analyzed. We present in Table 1 the baseline demographic and clinical 
characteristics of the study population. The age range of the cohort was 21 to 87 years old 
(mean, 60.6 years), males 51.6% and had type 2 diabetes (96.7%). Among the patients, 30 
(33.0%) were identified as ATSI and 70.3% of them were on insulin. The mean lowest BGL 
was 2.9 mmol/L (52.2 mg/dL) (range, 1.1-3.9 mmol/L; 20.0-70.0 mg/dL). A total of 44 (48.3%) 
patients had lowest BGL between 3.9 mmol/L (70.0 mg/dL) and 3.1 mmol/L (55.0 mg/dL), 
28 (30.8%) had BGL between 3.0 mmol/L (54 mg/dL) and 2.3 mmol/L (41.0 mg/dL), whereas 
the remaining 19 (20.9%) patient had a BGL ≤ 2.2 mmol/L (≤ 40 mg/dL) during their hospi-
talization. The mean number of hypoglycemic events with inpatient hypoglycemia was 2.9 
episodes/patient (range, 1-15 episodes/patient).
This cohort of patients shows a higher burden of comorbidity with an average CCI score 
of 7.2 (range, 1-15) and 86.81% had a CCI of ≥ 5. The mean LOS was 9.0 days (range, 0.3-
49.7). About one-third (36.3%) of the patients were treated with basal-bolus insulin regimen. 
Table 1 reveals no significant associations between baseline demographic (and clinical) char-
acteristics and readmission (and mortality). About one-half (53.9%) of the patients in this 
cohort had hypertension; other primary diagnosis and major comorbidities are presented in 
Table 2. Further summary of the data and the data fields are included in Table 3. Although 
non-ATSI had higher mortality and readmission, quantitative comparisons with ATSI were 
not statistically significant. We observed that, separately, comorbidity rates, LOS, and 
number hypoglycemia were significantly higher for non-ATSI than ATSI (Table 3).
The adjusted model for likelihood of readmission showed that gender, indigenous status, 
CCI, and BGL level were not significant risk factors for an increased readmission (Table 4). 
Having a CCI score between 3 and 4 did not reach nominal statistical significance (P = 0.06). 
However, readmitted patients were older (50-59 years vs < 50 years, P = < 0.05; 60-69 years 
vs < 50 years, P = < 0.12; 70 + years vs < 50 years, P = <0.05).
The results from multivariate Cox regression displayed in Table 4 shows that being of 
ATSI origin is associated with longer LOS (HR, 2.1; 95% CI, 1.2-3.5). Having severe hy-
poglycemia (≤ 2.2 mmol/L) is significantly associated with longer LOS (HR, 2.3; 95 CI%, 
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1.2–4.2) than mild hypoglycemia (3.9-3.1 mmol/L). No significant differences in LOS were 
found for gender, age, and CCI score.
3. Discussion
To the best of our knowledge, this is the first study to estimate, in a hospital-based Australian 
diabetic population, incidence of inpatient hypoglycemia on general ward admissions. It 
shows a high rate of hypoglycemia, 29.9% in our cohort, which is much higher than the 
3.5% to 10.5% reported by others [9, 13, 14]. In our series, 70% of the study population were 
treated with insulin, in contrast to 24.5% reported by others in earlier studies [8]. The rel-
atively higher rate of insulin-treated patients in our series might have contributed to high 
Table 1. Demographic and Clinical Characteristics of Patients with Hypoglycemia
Characteristics
Mean (Range)  
or  
N (%)a
Readmission  
OR (95% CI)
Mortality  
OR (95% CI)
Overall 91 20 (22.0%) 6 (6.6%)
Gender
 Male 47 (51.6%) 0.9 (0.3–2.5) 0.2 (0.0–1.2)
 Female 44 (48.4%) Reference Reference
 Age (years) 60.6 (21–87) 1.0 (0.9–1.0) 1.0 (0.9–1.0)
Age
  < 50 years 21 (23.1%) Reference Reference
 50–59 years 19 (20.9%) 0.1 (0.0–0.5) 2.9 (0.4–32.1)
 60–69 years 24 (26.4%) 0.3 (0.1–1.1) 1.5 (0.2–17.6)
 70+ years 27 (29.7%) 0.2 (0.1–0.7) 0.3 (0.0–4.9)
Surgical procedure 18 (19.8%) 1.1 (0.3–3.4) 0.5 (0.1–5.3)
No surgical procedure 73 (80.2%) Reference Reference
Indigenous statusb
 ATSI 30 (33.0%) 0.9 (0.3–2.4) 0.5 (0.1–2.8)
 Non-ATSI 61 (67.0%) Reference Reference
LOS 9.0 (0.3–49.7)   
Number of hypoglycemia 2.9 [1–15] 0.8 (0.5–1.0) 1.0 (0.5–1.2)
Mean lowest BGL 2.9 (1.1–3.9) 0.9 (0.4–1.8) 1.6 (0.5–6.5)
BGL group
 Mild (3.9–3.1 mmol/L) 44 (48.3%) Reference Reference
 Moderate (3.0–2.3 mmol/L) 28 (30.8%) 0.8 (0.2–2.4) 1.6 (0.3–8.2)
 Severe (≤ 2.2 mmol/L) 19 (20.9%) 1.2 (0.4–4.1) 0.3 (0.0–3.4)
CCI 7.2 [1–15] 0.9 (0.7–1.0) 1.1 (0.9–1.5)
CCI subgroups
 Mild: CCI score [1, 2] 6 (6.6%) Reference Reference
 Moderate: CCI score [3, 4] 6 (6.6%) 0.1 (0.0–2.5) 1.0 (0.0–81.0)
 Severe: CCI score (≥ 5) 79 (86.8%) 0.3 (0.1–1.5)  1.2 (0.5–28.5)
Number on insulin 66 (77.7%) 5.5 (0.9–32.6) 0.3 (0.1–1.4)
Hospital diabetes treatment
 Basal only 10 (11.0%) Reference Reference
 Basal + bolus 33 (36.3%) 1.0 (0.2–4.6) 2.4 (0.2–34.4)
 Mixed 26 (28.6%) 0.7 (0.2–3.4) 0.4 (0.0–75.5)
 Unknown 22 (24.2%)   
Types of diabetes
 T2DM 58 (63.7%)   
 T1DM 29 (31.8%)   
 Unknown 4 (4.4%)   
All the listed categories and variables were not statistically significant.
ATSI, Aboriginal and Torres Strait Islander Australians; BGL, blood glucose level; CCI, Carlson comorbidity index; 
CI, confidence interval; LOS, length of stay; OR, odds ratio; T1DM, type diabetes mellitus; T2DM, type 2 diabetes 
mellitus.
aNumber of events (percentage).
bAboriginal and/or Torres Strait Islander.
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Table 2. Characteristics of Subjects with Inpatient Hypoglycemia Showing Primary Diagnoses and 
Major Comorbidities at the Time of Admission
Variables n %
Primary diagnosis
 Infection 27 29.67
 Metabolic 24 26.37
 Cardiovascular 14 13.38
 Cancer 10 10.99
 Mental 6 6.59
 Musculoskeletal 10 10.99
Comorbiditiesa
 Hypertension 49 53.85
 Ischemic heart disease 25 27.47
 Dyslipidemia 23 25.27
 Osteoarthritis 15 16.48
 Depression 13 14.29
 Stroke 8 8.79
 Gastroesophageal reflux disease 9 9.89
aIncluding those with multiple comorbidities
Table 3. Demographic and Clinical Characteristics of Patients with Hypoglycemia Among ATSIa and 
Non-ATSI
Characteristics Total Non-ATSIa ATSIa 
Overall, n (%) 91 61(67.0%) 30 (33.0%)b
Mortality 6 (6.6%) 5 (83.3%) 1 (16.7%)
Readmission 20 (3.0%) 14 (70.0%) 6 (30.0%)
Gender, n (%)
 Male 47 (51.6%) 36 (76.6%) 11 (23.4%)
 Female 44 (48.4%) 25 (56.8%) 19 (43.2%)
Age, n (%)
  < 50 years 21 (23.1%) 13 (61.9%) 8 (38.1%)
 50–59 years 19 (20.9%) 8 (42.1%) 11 (57.9%)
 60–69 years 24 (26.4%) 17 (70.8%) 7 (29.2%)
 70+ years 27 (29.7%) 23 (85.2%) 4 (14.8%)
Surgical procedure, n (%) 18 (19.8%) 11 (61.1%) 7 (38.9%)b
No surgical procedure, n (%) 73 (80.2%) 52 (71.3%) 21 (28.8%)
BGL group, n (%)
 Mild (3.9–3.1 mmol/L) 44 (48.3%) 29 (65.9%) 15 (34.1%)
 Moderate (3.0–2.3 mmol/L) 28 (30.8%) 18 (64.3%) 10 (35.3%)c
 Severe (≤ 2.2 mmol/L) 19 (20.9%) 14 (73.7%) 5 (26.3%)c
CCI subgroups, n (%)
 Mild: CCI score [1, 2] 6 (6.6%) 3 (50.0%) 3 (50.0%)
 Moderate: CCI score [3, 4] 6 (6.6%) 4 (66.7%) 2 (33.3%)
 Severe: CCI score (≥ 5) 79 (86.8%) 54 (68.4%) 25 (31.7%)b
Age (years) 60.6 (21–87) 63.4 (27–9) 55 (21–8)b
LOS, mean (range) 9.0 (0.3–49.7) 10.9 (0.6–49.7) 5.17 (0.3–13.4)d
Number of hypoglycemia, mean (range) 2.9 [1–15] 3.5 [1–15] 2.0 [1–6]c
Mean lowest BGL, mean (range) 2.9 (1.1–3.9) 7.4 [1–14] 7.2 [1–15]
CCI, mean (range) 7.24 [1–15] 7.4 [1–14] 2.9 (1.3–3.9)
ATSI, Aboriginal and/or Torres Strait Islander; BGL, blood glucose level; CCI, Carlson comorbidity index; LOS, 
length of stay. 
aBased on the number of events within each category. Note that the first subcategory of a variable is the reference 
comparison.
bP < 0.05.
cP < 0.01.
dP < 0.001.
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incidence of inpatient hypoglycemia in our report. In support of our study, Umpierrez et al. 
[15] reported similar incidence in their report on admitted insulin-treated type 2 diabetic 
patients, suggesting medication as a contributing factor. However, Malawana et al. and the 
International Hypoglycemia Study Group reported no significant differences in occurrence 
of inpatient hypoglycemia between insulin-treated and non-insulin-treated patients [8, 16].
We have also shown ATSI diabetic patients with inpatient hypoglycemia having signifi-
cantly longer LOS compared with non-ATSI counterparts. Interestingly, as far as we know, 
this is the first report on association of increased LOS with ethnicity. Our finding is rele-
vant in that ATSI people are 5.7 times more likely to be hospitalized for diabetes and thus 
at risk of long LOS, than non-Indigenous people [1]. More research is needed to understand 
extent of racial differences in the association between inpatient hypoglycemia and LOS in 
the wider Australian diabetic population. This will assist in understanding other clinical 
and environmental risk factors to explain longer LOS among the diabetic ATSI patients. 
Future studies should assess avenues for addressing these potential causes of inpatient 
hypoglycemia in the indigenous diabetic inpatients and implement interventions to reduce 
hypoglycemia and LOS.
Our studies further highlight irrespective of ethnic background, severe hypoglycemia 
was associated with longer LOS as previously reported in the United Kingdom and United 
States [9, 12, 17]. The need to maintain higher or normal BGLs is further supported by 
previous landmark studies showing excess mortality in individuals with tighter glycemic 
control compared with those with higher glycemic levels [18, 19]. Although increased mor-
tality during and after admission was reported to be associated with inpatient hospital hy-
poglycemia [17, 20], there was no significant mortality in our cohort. The reason for this is 
not obvious, but might be due to a small sample size compared with earlier studies as well 
as high CCI, signifying high comorbidities in both subjects with and without hypoglycemia 
in our study population.
We have also shown older patients with inpatient hypoglycemia were less likely to be at 
risk of hospital readmission. Significance of this is not clear because readmission for other 
comorbidities as measured by CCI was not significant in our study. Despite Indigenous 
status with inpatient hypoglycemia being associated with long LOS, readmission within 
1  month of initial hospital admission did not appear to be a contributory risk factor in 
Table 4. Risk Factors for Readmission and Length of Hospital Stay Among Diabetic Subjects with 
Inpatient Hypoglycemia
Characteristics
Readmission Length of stay
OR (95% CI) HR (85% CI)
Gender (reference: female)
Male 1.2 (0.4–3.7) 0.8 (0.5–1.3)
Indigenous status (reference: NATSI)
ATSI 0.9 (0.3–2.8) 2.1 (1.2–3.5)a
Age (reference: <50 years)
 50–59 years 0.1 (0–0.6)b 0.7 (0.4–1.5)
 60–69 years 0.3 (0.1–1.2) 0.8 (0.4–1.7)
 70+ years 0.2 (0.1–0.8)b 0.7 (0.3–1.3)
CCI (reference: mild CCI score, 1–2)
 Moderate: CCI score [3, 4] 0.1 (0–3.6) 0.4 (0.1–1.3)
 Severe: CCI score (>5) 0.9 (0.1–7.8) 0.8 (0.3–2.3)
BGL group (reference: mild, 3.1–3.9 mmol/L)
 Moderate (2.3–3.0 mmol/L) 0.8 (0.2–2.9) 1.2 (0.7–2.0)
 Severe (≤ 2.2 mmol/L) 1 (0.3–3.9) 2.3 (1.2–4.2)a
ATSI, Aboriginal and Torres Strait Islander Australians; CI, confidence interval; HR, hazard ratio; NATSI, non-
Aboriginal and Torres Strait Islander Australian; OR, odds ratio.
aP < 0.01. 
bP < 0.05.
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diabetic ATSI subjects. This contrasts Zaccardi et  al.’s report showing higher rate of 
readmissions among Caribbean diabetic subjects compared with Caucasians [21]. In the 
same report, Asians (Bangladeshi, Pakistani, and Indian) were found to have lower risk of 
readmission compared with Caucasians thought to be due to less aggressive management 
of glucose in the Asian patients [22]. More studies on a larger population in our setting is 
needed to characterize these findings.
Our data have an important strength: being, to the best of our knowledge, the first study 
to focus on Indigenous and non-Indigenous Australian patients with diabetes hospitalized 
in a general ward, by far the largest group of inpatients at high risk of hypoglycemia. On 
the other hand, some study limitations should be noted. The absence of randomization of 
patients in diabetic inpatient hypoglycemic group is an inherent problem in observational 
studies. Although we cannot be certain that hypoglycemia is the determining factor for LOS 
in the Indigenous and non-Indigenous cohort’s analysis, matching the 2 patient groups on 
primary diagnosis and other background variables reduced confounding. In this retrospec-
tive study, although all patients had diabetes and were receiving antidiabetic medications 
including insulin, we cannot exclude the possibility that some non-antidiabetic medications 
and other conditions may have contributed to the inpatient hypoglycemia, for example, 
beta blockers, sepsis, or alcoholism, rather than antidiabetic medications alone. It is im-
portant to note that there is a limitation to retrospective studies in general. Observations 
derived from such studies may contain some missing information and thus may serve as a 
stimulus to further prospective work to clarify findings. Similarly, our study is based on a 
small sample of events, non-ATSI patients were twice higher than for ATSI patients, which 
is not surprising given that indigenous population is less than 10% of the local population 
[23]. The present study must be interpreted in the knowledge of the defects inherent in 
such studies. Despite these, we believe that our report is likely to be accurate because expe-
rienced health care professionals made the recordings; our results are in line with similar 
findings in other non-Caucasian diabetic inpatient populations [21].
4. Conclusion
Our results are significant for promoting awareness of the effect of ethnicity on inpa-
tient hypoglycemia risk. Intensification of strategies for prevention of hypoglycemia in-
cluding education, frequent glucose monitoring, and glycemic pattern recognition should 
be emphasized to minimize inpatient hypoglycemia, particularly in the identified high-risk 
indigenous population. Further prospective studies on a larger population are needed to 
verify our findings.
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